Genentech/Xoma Xanelim BLA delay
Executive Summary
Genentech/Xoma's Xanelim (efalizumab) BLA filing will be delayed beyond summer 2002, companies announce April 5. A pharmacokinetic study comparing Genentech-produced to Xoma-produced drug did not achieve statistical definition of comparability. Genentech had projected a summer 2002 BLA filing for the psoriasis therapy (1"The Pink Sheet" Jan. 21, p. 32)...